[Microalbuminuria in patients with type 2 diabetes mellitus and arterial hypertension: Possibilities of therapy].
The study covered 30 patients with type 2 diabetes mellitus associated with mild and moderate arterial hypertension and beginning diabetic nephropathy (Stage III in accordance with the classification developed by C. Mogensen). The purpose of the study was to evaluate the therapeutic effect of the new superselective fi-blocker nebivolol (nebilet) having NO-modulating activity on the patho-genetic links of the development of angiopathies in patients with type 2 diabetes mellitus and arterial hypertension. Sixteen-week nebivolol therapy caused a significant decrease in the level of gfycemia, blood pressure, and serum atherogenicity, and the rate of lipid peroxidation and an increase in basal vascular endothelial secretion of nitric oxide, resulting in diminished microalbuminuria.